Your browser is no longer supported. Please, upgrade your browser.
Kronos Bio, Inc.
Index- P/E- EPS (ttm)-2.34 Insider Own0.20% Shs Outstand54.51M Perf Week8.03%
Market Cap1.25B Forward P/E- EPS next Y-2.88 Insider Trans-71.75% Shs Float46.72M Perf Month24.63%
Income-128.00M PEG- EPS next Q-1.12 Inst Own68.90% Short Float8.95% Perf Quarter-3.03%
Sales- P/S- EPS this Y-438.30% Inst Trans12.47% Short Ratio15.59 Perf Half Y-13.47%
Book/sh7.78 P/B3.13 EPS next Y-3.60% ROA-29.50% Target Price42.25 Perf Year-
Cash/sh8.13 P/C3.00 EPS next 5Y- ROE-40.70% 52W Range18.02 - 39.60 Perf YTD-18.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.54% Beta-
Dividend %- Quick Ratio32.40 Sales past 5Y- Gross Margin- 52W Low35.07% ATR1.42
Employees90 Current Ratio32.40 Sales Q/Q- Oper. Margin- RSI (14)66.44 Volatility7.95% 6.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-81.60% Profit Margin- Rel Volume0.70 Prev Close23.98
ShortableYes LT Debt/Eq0.00 EarningsAug 12 AMC Payout- Avg Volume268.29K Price24.34
Recom1.80 SMA2014.36% SMA5015.75% SMA200-7.15% Volume187,990 Change1.50%
Jun-24-21Initiated H.C. Wainwright Buy $35
Nov-03-20Initiated Piper Sandler Overweight $50
Nov-03-20Initiated Jefferies Buy $36
Nov-03-20Initiated Goldman Buy $45
Nov-03-20Initiated Cowen Outperform
Sep-14-21 08:00AM  
Sep-07-21 07:00AM  
Aug-12-21 04:05PM  
Jul-27-21 05:36PM  
Jul-12-21 04:56AM  
May-26-21 08:00AM  
May-25-21 08:00AM  
May-11-21 04:05PM  
May-06-21 08:00AM  
Apr-11-21 05:53AM  
Apr-10-21 08:30AM  
Mar-31-21 11:25AM  
Mar-26-21 08:00AM  
Mar-23-21 04:05PM  
Mar-10-21 04:35PM  
Mar-04-21 08:12AM  
Feb-25-21 08:00AM  
Feb-22-21 08:00AM  
Jan-26-21 08:00AM  
Jan-11-21 02:46AM  
Dec-08-20 08:00AM  
Dec-07-20 08:00AM  
Nov-23-20 08:00AM  
Nov-18-20 08:00AM  
Nov-11-20 08:00AM  
Nov-08-20 11:04AM  
Oct-22-20 08:00AM  
Oct-14-20 04:05PM  
Oct-09-20 03:49PM  
Oct-08-20 08:00PM  
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dinsmore ChristopherChief Scientific OfficerSep 07Option Exercise3.279,18930,048105,549Sep 09 01:23 PM
Dinsmore ChristopherChief Scientific OfficerSep 07Sale21.919,189201,30296,360Sep 09 01:23 PM
De Backer MarianneDirectorAug 20Buy19.571,00019,5651,600Aug 24 07:24 PM
Dinsmore ChristopherChief Scientific OfficerAug 02Option Exercise3.279,18930,048105,549Aug 03 05:13 PM
Dinsmore ChristopherChief Scientific OfficerAug 02Sale20.599,189189,16596,360Aug 03 05:13 PM
De Backer MarianneDirectorMay 28Buy25.0160015,006600Jun 01 04:08 PM
Loven JakobDirectorApr 20Sale20.1021,551433,1851,301,537Apr 20 06:59 PM
Loven JakobDirectorApr 19Sale20.5914,004288,2781,323,088Apr 20 06:59 PM
Loven JakobDirectorApr 16Sale21.0133,162696,7621,337,092Apr 20 06:59 PM
Loven JakobDirectorApr 15Sale21.7824,818540,5361,370,254Apr 15 06:57 PM
Loven JakobDirectorApr 14Sale22.8032,636744,0291,395,072Apr 15 06:57 PM
Loven JakobDirectorApr 13Sale23.8417,020405,7931,427,708Apr 15 06:57 PM
Loven JakobDirectorApr 12Sale26.2815,828415,8961,444,728Apr 12 08:33 PM
Loven JakobDirectorApr 09Sale27.2021,660589,1521,460,556Apr 12 08:33 PM
Loven JakobDirectorApr 08Sale27.4163,1281,730,4871,482,216Apr 12 08:33 PM
Omega Fund V, L.P.10% OwnerOct 14Buy19.00450,0008,550,0003,818,283Oct 16 03:58 PM
Stampacchia OtelloDirectorOct 14Buy19.00450,0008,550,0003,818,283Oct 16 03:56 PM
Ridloff ElenaDirectorOct 14Buy19.002,63049,9702,630Oct 16 03:52 PM
MARTIN JOHN CDirectorOct 14Buy19.0075,8001,440,2001,952,364Oct 16 03:51 PM
Kosacz BarbaraCOO & General CounselOct 14Buy19.005,25099,750614,600Oct 16 03:40 PM
Dinsmore ChristopherChief Scientific OfficerOct 14Buy19.005,25099,7505,250Oct 16 03:39 PM
Al-Wakeel Yasir B.Chief Financial OfficerOct 14Buy19.005,25099,75037,219Oct 16 03:38 PM
Bischofberger Norbert W. & Ing10% OwnerOct 14Buy19.0095,5001,814,5004,370,496Oct 16 03:36 PM
BISCHOFBERGER NORBERT WPresident & CEOOct 14Buy19.0095,5001,814,5004,370,496Oct 16 03:29 PM